Follow us on Twitter
twitter icon@FreshPatents

Browse patents:
Next
Prev

Use of a polymorph of flibanserin for treating disease




Title: Use of a polymorph of flibanserin for treating disease.
Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments. ...


Browse recent Sprout Pharmaceuticals, Inc. patents


USPTO Applicaton #: #20120270883
Inventors: Carlo Bombarda, Enrica Dubini, Antoine Ezhaya


The Patent Description & Claims data below is from USPTO Patent Application 20120270883, Use of a polymorph of flibanserin for treating disease.

RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 10/210,474, filed Aug. 1, 2002, which claims, as does the present application, benefit of U.S. Provisional Application Ser. No. 60/329,435, filed on Oct. 15, 2001, European Patent Application EP 01 118 593, filed Aug. 2, 2001, and European Patent Application EP 01 130 180, filed Dec. 19, 2001, the disclosures of all of which are incorporated by reference in their entireties.

FIELD OF THE INVENTION

- Top of Page


The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.

BACKGROUND

- Top of Page


OF THE INVENTION

The compound 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one (flibanserin) is disclosed in form of its hydrochloride in European Patent Application EP-A-526434 and has the following chemical structure:

Flibanserin shows affinity for the 5-HTIA and 5-HT2-receptor. It is therefore a promising therapeutic agent for the treatment of a variety of diseases, for instance depression, schizophrenia, Parkinson, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment.

A certain pharmaceutical activity is of course the basic prerequisite to be fulfilled by a pharmaceutically active agent before same is approved as a medicament on the market. However, there are a variety of additional requirements a pharmaceutically active agent has to comply with. These requirements are based on various parameters which are connected with the nature of the active substance itself. Without being restrictive, examples of these parameters are the stability of the active agent under various environmental conditions, its stability during production of the pharmaceutical formulation and the stability of the active agent in the final medicament compositions. The pharmaceutically active substance used for preparing the pharmaceutical compositions should be as pure as possible and its stability in long-term storage must be guaranteed under various environmental conditions. This is absolutely essential to prevent the use of pharmaceutical compositions which contain, in addition to the actual active substance, breakdown products thereof, for example. In such cases the content of active substance in the medicament might be less than that specified.

Uniform distribution of the medicament in the formulation is a critical factor, particularly when the medicament has to be given in low doses. To ensure uniform distribution, the particle size of the active substance can be reduced to a suitable level, e.g. by grinding. Since breakdown of the pharmaceutically active substance as a side effect of the grinding (or micronising) has to be avoided as far as possible, in spite of the hard conditions required during the process, it is absolutely essential that the active substance should be highly stable throughout the grinding process. Only if the active substance is sufficiently stable during the grinding process is it possible to produce a homogeneous pharmaceutical formulation which always contains the specified amount of active substance in reproducible manner.

Another problem which may arise in the grinding process for preparing the desired pharmaceutical formulation is the input of energy caused by this process and the stress on the surface of the crystals. This may in certain circumstances lead to polymorphous changes, to a change in the amorphous configuration or to a change in the crystal lattice. Since the pharmaceutical quality of a pharmaceutical formulation requires that the active substance should always have the same crystalline morphology, the stability and properties of the crystalline active substance are subject to stringent requirements from this point of view as well.

The stability of a pharmaceutically active substance is also important in pharmaceutical compositions for determining the shelf life of the particular medicament; the shelf life is the length of time during which the medicament can be administered without any risk. High stability of a medicament in the abovementioned pharmaceutical compositions under various storage conditions is therefore an additional advantage for both the patient and the manufacturer.

Apart from the requirements indicated above, it should be generally borne in mind that any change to the solid state of a pharmaceutical composition which is capable of improving its physical and chemical stability gives a significant advantage over less stable forms of the same medicament.

The aim of the invention is thus to provide a new, stable crystalline form of the compound flibanserin which meets the stringent requirements imposed on pharmaceutically active substances as mentioned above.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 shows the X-ray powder diffraction pattern of polymorph A of flibanserin.

DETAILED DESCRIPTION

- Top of Page


OF THE INVENTION

Surprisingly, it has been found that the free base of flibanserin in a specific polymorphic form fulfills the requirements mentioned hereinbefore.

Moreover it has been found that, depending on the choice of conditions which can be applied during the synthesis of flibanserin the free base occurs in different crystalline modifications, polymorphs A and B.

It has been found that these different modifications can be deliberately produced by a suitable choice of the process conditions used in the manufacturing process.

Surprisingly, it has been found that polymorph A, which can be obtained in crystalline form by choosing specific reaction conditions, meets the stringent requirements mentioned above and thus solves the problem on which the present invention is based. Accordingly the present invention relates to polymorph A of flibanserin.

Polymorph A of flibanserin is characterised by a melting point of about 161° C. (determined via DSC; heating rate 10 K/min). 161° C. as determined using DSC.

Polymorph B, the less stable modification of flibanserin displays a melting point of about 120° C. (determined via DSC; heating rate 10 K/min). Whereas polymorph B shows little stability under the effects of for instance mechanical stress produced by grinding, polymorph A turned out to fulfill the aforementioned stability requirements.

According to another aspect, the present invention relates to a process for the manufacture of polymorph A of flibanserin in technical scale. The process according to the invention is illustrated in diagram 1.




← Previous       Next →
Advertise on FreshPatents.com - Rates & Info


You can also Monitor Keywords and Search for tracking patents relating to this Use of a polymorph of flibanserin for treating disease patent application.

###


Browse recent Sprout Pharmaceuticals, Inc. patents

Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Use of a polymorph of flibanserin for treating disease or other areas of interest.
###


Previous Patent Application:
Fluorinated derivates of 3-hydroxypyridin-4-ones
Next Patent Application:
Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
Industry Class:
Drug, bio-affecting and body treating compositions
Thank you for viewing the Use of a polymorph of flibanserin for treating disease patent info.
- - -

Results in 0.13676 seconds


Other interesting Freshpatents.com categories:
Amazon , Microsoft , Boeing , IBM , Facebook

###

Data source: patent applications published in the public domain by the United States Patent and Trademark Office (USPTO). Information published here is for research/educational purposes only. FreshPatents is not affiliated with the USPTO, assignee companies, inventors, law firms or other assignees. Patent applications, documents and images may contain trademarks of the respective companies/authors. FreshPatents is not responsible for the accuracy, validity or otherwise contents of these public document patent application filings. When possible a complete PDF is provided, however, in some cases the presented document/images is an abstract or sampling of the full patent application for display purposes. FreshPatents.com Terms/Support
-g2-0.4744

66.232.115.224
Browse patents:
Next
Prev

stats Patent Info
Application #
US 20120270883 A1
Publish Date
10/25/2012
Document #
File Date
12/31/1969
USPTO Class
Other USPTO Classes
International Class
/
Drawings
0


Flibanserin

Follow us on Twitter
twitter icon@FreshPatents

Sprout Pharmaceuticals, Inc.


Browse recent Sprout Pharmaceuticals, Inc. patents



Drug, Bio-affecting And Body Treating Compositions   Designated Organic Active Ingredient Containing (doai)   Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai   Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.)   1,4-diazine As One Of The Cyclos   Piperazines (i.e., Fully Hydrogenated 1,4-diazines)   Additional Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding  

Browse patents:
Next
Prev
20121025|20120270883|use of a polymorph of flibanserin for treating disease|The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments. |Sprout-Pharmaceuticals-Inc
';